Immunogenic cell death: an emerging target in gastrointestinal cancers

M Chiaravalli, A Spring, A Agostini, G Piro, C Carbone… - Cells, 2022 - mdpi.com
Immunogenic cell death (ICD) is a regulated form of cell death that induces the activation of
both innate and adaptive immune responses through the release of damage-associated …

Targeting tumour-reprogrammed myeloid cells: the new battleground in cancer immunotherapy

F De Sanctis, A Adamo, S Canè, S Ugel - Seminars in Immunopathology, 2023 - Springer
Tumour microenvironment is a complex ecosystem in which myeloid cells are the most
abundant immune elements. This cell compartment is composed by different cell types …

Hydroxyapatite nanoparticles promote TLR4 agonist-mediated anti-tumor immunity through synergically enhanced macrophage polarization

R Wang, Y Hua, H Wu, J Wang, Y Xiao, X Chen, Q Ao… - Acta Biomaterialia, 2023 - Elsevier
Macrophages represent the most prevalent immune cells in the tumor micro-environment,
making them an appealing target for tumor immunotherapy. One of our previous studies …

CXCR1/2 dual-inhibitor ladarixin reduces tumour burden and promotes immunotherapy response in pancreatic cancer

G Piro, C Carbone, A Agostini, A Esposito… - British Journal of …, 2023 - nature.com
Background Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with
few therapeutic options available. Despite immunotherapy has revolutionised cancer …

Enhancing HCC Treatment: innovatively combining HDAC2 inhibitor with PD-1/PD-L1 inhibition

R Han, C Ling, Y Wang, L Lu - Cancer Cell International, 2023 - Springer
Hepatocellular carcinoma (HCC) is a malignancy with high morbidity and mortality but lacks
effective treatments thus far. Although the emergence of immune checkpoint inhibitors in …

Activated Natural Killer Cells‐Dependent Dendritic Cells Recruitment and Maturation by Responsive Nanogels for Targeting Pancreatic Cancer Immunotherapy

J Deng, W Xu, S Lei, W Li, Q Li, K Li, J Lyu, J Wang… - Small, 2022 - Wiley Online Library
Although enormous success has been obtained for dendritic cells (DCs)‐mediated antigen‐
specific T cells anticancer immunotherapy in the clinic, it still faces major challenging …

The role of toll-like receptors (TLRs) mediated inflammation in pancreatic cancer pathophysiology

A Orlacchio, P Mazzone - International Journal of Molecular Sciences, 2021 - mdpi.com
Pancreatic cancer (PC) is one of the most lethal forms of cancer, characterized by its
aggressiveness and metastatic potential. Despite significant improvements in PC treatment …

Immunotherapeutic implications of toll-like receptors activation in tumor microenvironment

R Zheng, J Ma - Pharmaceutics, 2022 - mdpi.com
Toll-like receptors (TLRs) play an important role between innate and adaptive immunity as
one of the pattern recognition receptors (PRRs). Both immune cells and tumor cells express …

In situ vaccination using unique TLR9 ligand K3-SPG induces long-lasting systemic immune response and synergizes with systemic and local immunotherapy

H Okada, K Takahashi, H Yaku, K Kobiyama… - Scientific Reports, 2022 - nature.com
Although checkpoint inhibitors (CPIs) have changed the paradigm of cancer therapy, low
response rates and serious systemic adverse events remain challenging. In situ vaccine …

Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment in pancreatic cancer

A Agostini, I Guerriero, G Piro, G Quero… - Journal of Translational …, 2023 - Springer
Background Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease. This is due to its
aggressive course, late diagnosis and its intrinsic drugs resistance. The complexity of the …